Aurobindo Pharma's subsidiary, Auro Pharma, has acquired the non-oncology prescription formulations business of Khandelwal Laboratories for Rs 325 crore. The deal includes 23 brands and nine pipeline products, primarily in anti-infective and pain management, which generated Rs 113.53 crore in FY2024-25. This acquisition aims to bolster Aurobindo's domestic market presence in key therapeutic areas.